Recentstudieshaveconfirmedtheroleoftumor-infiltratinglymphocytes(TILs)in carcinogenesisandcancerprogression.Theaimofthisstudywastoevaluatethe correlation between the level of tumor lymphocyte infiltration and well-known clinicopathologicalfactorsinbreastcancerpatients.Wealsoevaluatedtheinfluence of TILs on overall survival. Paraffin sections were retrospectively evaluated in76casesinearlystagebreastcancerpatientswhounderwentsurgeryfollowed by systemic treatment. Tumor-infiltrating lymphocytes were classified as absent (grade 0), mild (grade 1), moderate (grade 2), or severe (grade 3). Tumor-infiltratinglymphocyteswerefoundin87%ofpatients(severegradein8%ofthem). Highergrade(grades2-3)TILswerepresentmorefrequentlyinyoungerpatients (under65years)thanolderwomen(47%vs.24%;p=0.099).Highergradesof tumor-infiltratinglymphocytes(grades2-3)appeartobeassociatedwithclinicopathologicalfactorssuchasnegativesteroidreceptorstatus(p=0.001),HER2 overexpression(p=0.016)andhigherhistologicalgrade(G3)(p=0.095).Tumor-infiltrating lymphocytes were not a significant prognostic factor for overall survivalinourgroup.OnlyHER2overexpressionsignificantlyincreasestheriskof death(HR=4.3,p=0.020).Inthesubgroupofpatientswhohadtumorswith HER2overexpressiontherewasnon-significantlyworseOSindependentlyofTIL grade(p=0.086).
Introduction
Tumor formation, growth, invasion and metastasisofcanceranditsmalignanciesdependonthebiologicalfeaturesofcanceranditsinteractionswiththe microenvironment. The well-known biological prognosticfactorsincludehistologicalgrade,expressionof thehormonereceptors(estrogenreceptorandprogesterone receptor), proliferation marker Ki67 and amplificationstatusoftheHER2gene [1, 2] .Thetumor microenvironment such as adipocytes, tumor-associated fibroblasts, immune cells, extracellular matrix, cytokinesandtumor-associatedmacrophages(TAMs) arefoundtoplayimportantrolesincarcinogenesisand cancer progression (tumor formation, growth, invasion,motilityandintravasation) [3, 4] .
Recentstudieshaveconfirmedtheroleoftumor-infiltrating lymphocytes (TILs) in carcinogenesis and cancer progression [5, 6] . Most conducted analyses concernedtheinfluenceofTILsonprognosisandresponsetoneoadjuvanttherapy [7, 8] .Anassociation between TILs and treatment response was reported insomestudies.Increasedstromallymphocyteinfiltrationsignificantlyimprovedpathologicalcomplete response(pCR)(36.6%)ratesafteranthracycline/taxanechemotherapyintheNeoadjuvantGeparQuinto Trial [9] .Loiet al.reportedthatTILswereassociated withhigherpCRratesafterneoadjuvanttrastuzumab and chemotherapy in early-stage HER2-positive breastcancer.InHER2-positivebreastcancer,there was described a significant interaction between increasing TILs and benefit with anthracycline-based chemotherapy [10] . The FinHER trial reported the influenceofhigherlevelsofTILsonincreasedtrastuzumab benefit in HER2+ breast cancer (each 10% increaseofTILswasassociatedwithan18%reduc-tion in risk of distant recurrence). The group with higherTILsinbaselinesampleshadabetterresponse totrastuzumabtreatment.Theresultsalsoconfirmed theassociationbetweenTILsanddecreaseofdistant recurrence rates in primary triple negative breast cancer [11] .
Previous research has shown the relationship betweensomesubtypesofTILandbreastcancersurvival.MassiveinfiltrationofCD8cellsisanimportant component of antitumor immunity and is associatedwithabetterprognosis.Incontrast,tumorswith severeinfiltrationofregulatoryTcellstendtohave a worse prognosis [12, 13] . Moreover, the presence of CD8+ infiltration causes a significant reduction intheriskofdeathinERnegativeorERandHER2 positivesubtypes [14] .
As for now, total TILs in breast cancer are not found to be strongly associated with clinicopathologicalfeatures [15] .However,somestudiesshowed a higher level of TILs in breast cancer with HER2 overexpression, negative steroid receptor status and highhistologicaldifferentiation [7] .Theaimofthis study was to evaluate the correlation between the leveloftumorlymphocyteinfiltration(gradedfrom 0to3)andwell-knownclinicopathologicalfactorsin breast cancer patients. We also evaluated the influenceofTILsonoverallsurvival(OS). [19] .Lymphocyticinfiltrationswereclassifiedas absent(grade0),mild(grade1),moderate(grade2), orsevere(grade3) (Fig.1A ,B,C,D).Withascore of0,inflammatorycellsweresingleorabsentatthe tumor; score 1 indicated mild and dispersed lymphocytepresence,includinginsmallgroups;score2 denoteddiffuseandclearlyvisiblelymphocyteinfiltrationattheinvasivemargin;score3revealeddense andprominentfloridlymphocyticinfiltrationatthe invasiveedgewithdestructionofcancercells.These variables were evaluated for their association with clinicopathologicalfeatures.
Materials and methods

Paraffinsectionswereretrospectivelyevaluatedin
StatisticalanalysiswascarriedoutusingSTATIS-TICA 7 software. The frequency of side effects was counted. The qualitative features were presented as the percentage of their occurrence and evaluatedwithFisher'sexacttestandmultivariateanalysis used logistic regression. Overall survival (OS) was measured from the date of diagnosis to the date of thelastfollow-upordeath.Survivalevaluationwas performed using the Kaplan-Meier estimator with the log rank test. Prognostic factors of overall survivalwereestimatedbytheCoxproportionalhazards model.Differenceswereconsideredsignificantifthe pvaluewas≤0.05.
Results
Tumor-infiltrating lymphocytes were present in 87% (66/76) of patients. Severe grade infiltration (3grade)wasdetectedin7%(5/76)ofthem.Grade 1 and grade 2 TILs were reported in 45% and in 35%, respectively. Tumor-infiltrating lymphocytes Inpatientswiththepresenceoflymphnodemetastases,tumorinfiltrationwaspresentinsignificantlymoreoftenthaninthegroupwithoutmetastases (95%vs.84%;p=0.436).Inouranalysis,therewas non-significantly higher presence of grade 2 and 3 TILs in cases of contralateral breast cancer than in one-side breast cancer (71% vs. 39%; p = 0.124). Therewasnosignificantassociationbetweentumor size and TILs. There was non-significantly higher presence of TIL grade 2-3 in tumors of larger size (T3-4)incomparisontoT2andT1tumors(75%vs. 35% vs. 44%, p = 0.365). Disease recurrence was detectedin9%ofpatients.Mostofthemhadtumors with lymphocyte infiltration (grades 1-3). Higher histologicalgrade(G3)wasdetectednon-significantlymoreoftenintumorswithTILgrades2-3incom-parison to lower histological grades (G1-G2) (57% vs.36%,p=0.095).
In logistic regression analysis, significant factors foroccurrenceofgrade2and3TILswerenegative steroid receptor status (OR =5.8, p = 0.002) and HER2 overexpression (OR= 5.4, p = 0.005). ResultsoflogisticanalysisareshowninTableIII. There wasobservednoassociationbetweenOS(p=0.567) andlymphocyteinfiltration(TILs)inthewholestudiedgroup (Fig.2) .Inthesubgroupofpatientswho hadtumorswithHER2overexpressionOSwasworse in comparison to patients with HER2 negative tumors(p=0.016)(5-yearOS87.8%vs.96.0%and 7-year65.7%vs.91.7%) (Fig.2) .Patientswithtumor HER2 overexpression had 4-fold higher risk of death than patients with HER negative tumors (HR=4,32,p=0.020).Therewasobservednosig- nificant difference according to OS (p = 0.567) in TILsubgroups(TILgrades2-3vs.TIL0-1)(5-year OS86.6%vs.97.7%and7-year82.5%vs.85.7%) (Fig.2) .Inthesubgroupofpatientswhohadtumors with HER2 overexpression there was non-significantly worse OS independently of TIL grade (p = 0.086) (Fig.3) .TNBCwasobservedin15patients in our group (10 patients with TIL grades 2-3 and 5patientswithTILgrade1tumors).Follow-uptime ofTNBCwomenwascomparable.Itwasrespectively 67,7-106,0monthsforpatientswithTILgrade1 tumors and 14, 5-111, 1 months for patients with TILgrade2-3tumors.
Discussion
In this retrospective study, we found that TILs were significantly associated with clinicopathological factors such as negative steroid receptor status (p=0.001),HER2overexpression(p=0.016)and thepresenceofhigherhistologicalgrade-G3(p= 0.095).InlogisticregressionanalysisHER2overex-pressionandnegativesteroidreceptorstatuswereindependentfactorsthatincreasetheriskofoccurrence of TILs. In previous analysis general inflammatory cellinfiltrationwasassociatedwithhighgrade,negativesteroid(ERandPR)receptorstatusandthepresenceofvascularinvasion [16] .AhigherlevelofTILs wasdescribedinbreastcancerwithhigherdifferentiation,negativehormonereceptorstatusandHER2 overexpression [7] . An association between BRCA1 mutation and TILs was detected in ovarian cancer [17] .Theauthorsdidnotfindsuchanassociationfor breast cancer. In our study the BRCA1/2 mutation wasdetectedin6(8%)patients.TILs(grades1and 2)wereobservedinallmutationcarriers.Therewas no association between TIL grade and the presence ofBRCA1/2mutation(TILs0-1vs.TILs2-3)(p= 0.692).
In the analyzed group, there was observed a differenceinlymphocyteinfiltrationbetweenhistologicalsubgroups.TumorswithhigherTILs(grades2-3) were reported in 20% of luminal A breast cancer type, in 28% of luminal B type, in 67% of TNBC type,andin89%ofnon-luminalbreastcancertype.
The BIG 02-98 trial showed an association between higher lymphocytic infiltration and benefit withchemotherapy(highdoseanthracyclinetherapy or combination anthracycline-docetaxel regimens) in HER2-positive breast cancer [10] . The FINHER study reported that strong TILs resulted in greater responsestotrastuzumabtreatment [11] .
Tumor-infiltrating lymphocytes seems to be predictive factor forplatinum-basedneoadjuvantchemotherapy,especially in TNBC [18] . Loi S et al. described an association between higher pCR rate after neoadjuvant therapy with trastuzumab and TILs [11] . In our study we analyzed only early breast cancer patients whoreceivedsystemicadjuvanttherapy.Wedidnot evaluatetheresponsetoneoadjuvanttreatment.
InsomestudiesTILsweresignificantlyassociated with good prognosis in TNBC. Some data suggest thathighlevelsofTILsarealsoassociatedwithbetteroutcomesinHER2-positivebreastcancerpatients treatedwithtrastuzumabaswellasdualtrastuzumab and lapatinib with chemotherapy [7, 11] . These findingsweresupportedbythelargephaseIIIBIG 02-98trial.ApositiveassociationbetweenTILsand survival independent of clinicopathological characteristics in primary operable ductal invasive breast cancerwasdescribedbyMohammedet al. [16] .High levels of TILs correlate with increased disease-free survival (DFS) after adjuvant anthracycline-based chemotherapy [13] .IntheECOGtrials(E2197and E1199)multivariableanalysisconfirmedTILstobe an independent prognostic marker of DFS, DRFI (distantrecurrence-freeinterval)andOS(overallsurvival) for TNBCs. In this group higher TIL scores wereassociatedwithbetterprognosis;forevery10% increase in TILs, a 14% reduction of risk of recurrenceordeath(p =0.02),an18%reductionofrisk ofdistantrecurrence(p =0.04),anda19%reduction ofriskofdeath(p =0.01)weredescribed [19] .As fornow,thestrongestassociationofTILsandbreast cancer outcome has been observed for TNBC patients who received adjuvant anthracycline-containing chemotherapy. Certain types of chemotherapy (anthracyclines,oxaliplatin,gemcitabine)areableto induce immunogenic cell death which can promote a cytotoxic T lymphocyte responses and antitumor immunity [20, 21] . The induction of immunologic cell death may influence long remission. TILs were notasignificantprognosticfactorforoverallsurvivalinallourgroup.Inthesubgroupofpatientswho hadtumorswithHER2overexpression(treatedwith anthracycline-basedchemotherapythenwithtrastuzumab) there was observed non-significantly worse OSindependentlyofTILgrade(p=0.086).TNBC wasobservedin15patientsinourgroup(10patients withTILgrades2-3and5patientswithTILgrade1 tumors).Follow-uptimeofTNBCwomenwascomparable.Itwasrespectively67,7-106,0monthsfor patientswithTILgrade1tumorsand14,5-111,1 monthsforpatientswithTILgrade2-3tumors.
The first recommendation for assessing TILs in breastcancerwaspreparedbyanInternationalTILs Working Group 2014. This article presents a summary of the adjuvant and neoadjuvant studies that haveassessedTILsasaprognosticorpredictivefactor andmethodologicalrecommendationsforevaluating TILsinbreastcancer.However,sofarnoformalrecommendation for clinical practice according to the roleofTILscanbegiven.Theresultsofrecentstudies arenotyetreadytochangeclinicalpractice.Further researchiswarranted.
Conclusions
Tumor-infiltratinglymphocytesappeartobeassociatedwithclinicopathologicalfactorssuchasnegativesteroidreceptorstatus(p=0.001),HER2over-expression (p = 0.016), younger age (< 65 years) (p=0.099)andhigherhistologicalgrade(G3)(p= 0.095).TILswerenotasignificantprognosticfactor for overall survival in our group. Only HER2 overexpression significantly increased the risk of death (HR=4.3,p=0.020).Inthesubgroupofpatients who had tumors with HER2 overexpression there wasnon-significantlyworseOSindependentlyofTIL grade(p=0.086).
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